Virginia Powers, PhD

The occurence of hand-foot skin response could signal regorafenib activity in hepatocellular cancer.

A trial testing the combination of ublituximab, ibrutinib, and umbralisib showed that the combination was well tolerated and had activity across patients with high-risk B-cell malignancies.

The clinical benefits and safety profiles for ribociclib remained consistent when treating both younger and elderly patients with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.

Regorafenib was found to improve overall survival by nearly 3 months for patients with previously treated hepatocellular carcinoma.

Though having a high body mass index is associated with a higher risk for colorectal cancer, patients who are thinner may not do as well after treatment for metastatic colorectal cancer.